S. Sundstrøm

发表

Photodynamic therapy with 5‐aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6‐year clinical and histological follow‐up

T. Viset, T. Warloe, E. Christensen, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.

R. Bremnes, O. Brustugun, B. Grønberg, 2018, Anticancer research.

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

L. Ek, R. Bremnes, B. Bergman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral versus intravenous vinorelbine in advanced NSCLC—a retrospective comparison

R. Bremnes, B. Grønberg, N. Helbekkmo, 2016 .

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

R. Hatlevoll, S. Kaasa, S. Aamdal, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study

L. Ek, R. Bremnes, B. Bergman, 2007 .

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.

R. Hatlevoll, S. Kaasa, S. Aamdal, 2001, Lung cancer.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer

R. Bremnes, O. Brustugun, B. Grønberg, 2016, Acta oncologica.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer

S. Kaasa, R. Bremnes, O. Brustugun, 2016, Acta oncologica.

Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

S. Kaasa, R. Bremnes, O. Brustugun, 2016, Lung cancer.

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

K. Krejcy, T. Ciuleanu, A. Knuuttila, 2012, Lung cancer.

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group

R. Bremnes, T. Amundsen, T. Wentzel‐Larsen, 2012, British Journal of Cancer.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

S. Kaasa, R. Bremnes, T. Amundsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Breast-preserving surgery--always the right choice?].

S. Sundstrøm, 2013, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[Occupational lung cancer in Sør-Trøndelag county].

T. Amundsen, S. Sørhaug, B. Hilt, 2014, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study.

P. Fayers, S. Kaasa, R. Bremnes, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.

R. Bremnes, N. Helbekkmo, U. Aasebø, 2015, Clinical lung cancer.

Did Survival Improve after the Implementation of Intraoperative Neuronavigation and 3D Ultrasound in Glioblastoma Surgery? A Retrospective Analysis of 192 Primary Operations

S. Torp, O. Solheim, G. Unsgård, 2012, Journal of Neurological Surgery—Part A.

Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment

J. Sørensen, S. Sundstrøm, Katharina Perell, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.

R. Bremnes, U. Aasebø, S. Sundstrøm, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[An outbreak of ornithosis. The military camp in Porsanger in 1982].

P. Jenum, A. Bruu, S. Sundstrøm, 1986, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

206 Treatment of limited small cell lung cancer (SCLC) with paclitaxel, cisplatin, etoposide and radiation therapy

R. Bremnes, U. Aasebø, S. Sundstrøm, 1997 .

Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.

S. Torp, Ø. Salvesen, S. Sundstrøm, 2015, Journal of neurology, neurosurgery, and psychiatry.

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma

E. Anderssen, K. Dobra, T. Amundsen, 2012, PloS one.

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy

R. Bremnes, N. Helbekkmo, U. Aasebø, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

K. Nackaerts, R. Stahel, A. Santoro, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

S. Aamdal, C. Kersten, G. Gaudernack, 2011, Clinical Cancer Research.

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

Bernard Rachet, Erik Jakobsen, Camille Maringe, 2013, Thorax.

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

R. Bremnes, T. Amundsen, C. von Plessen, 2009, Lung cancer.

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

R. Bremnes, B. Bergman, C. von Plessen, 2006, British Journal of Cancer.

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.

R. Bremnes, C. von Plessen, N. Helbekkmo, 2008, Lung cancer.

Does chemotherapy improve Quality of Life in NSCLC PS 2

R. Bremnes, N. Helbekkmo, U. Aasebø, 2009 .

Chemotherapy and quality of life in NSCLC PS 2 patients

R. Bremnes, C. von Plessen, N. Helbekkmo, 2009, Acta oncologica.

Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study

N. Wilking, E. Omenaas, T. Wentzel‐Larsen, 2008, Thorax.

Histopathology and prognosis in human meningiomas

Thomas Backer-Grøndahl, Bjørnar H Moen, S. Torp, 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity

R. Bremnes, C. von Plessen, N. Helbekkmo, 2007, British Journal of Cancer.

C5-01: Open-label study of pemetrexed alone or in combination with a platinum in chemonaïve patients (pts) with malignant pleural mesothelioma (MPM): Results from the International Expanded Access Program (EAP)

K. Nackaerts, R. Stahel, A. Santoro, 2007 .

Endoanal Ultrasound is of Little Value in Follow-Up of Anal Carcinomas

R. Haaverstad, A. Wibe, J. Lund, 2004, Diseases of the colon and rectum.

Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.

S. Kaasa, R. Bremnes, T. Amundsen, 2010, European journal of cancer.

Can dogs smell lung cancer? First study using exhaled breath and urine screening in unselected patients with suspected lung cancer

R. Haaverstad, O. Gederaas, T. Amundsen, 2014, Acta oncologica.

Prognostic value of histological features in diffuse astrocytomas WHO grade II.

S. Torp, S. Sundstrøm, T. Lind-Landström, 2012, International journal of clinical and experimental pathology.

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.

P. Fayers, R. Hatlevoll, S. Kaasa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palliative External Beam Thoracic Radiation Therapy of Non-Small Cell Lung Cancer

S. Sundstrøm, 2011 .

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

R. Hatlevoll, S. Kaasa, S. Aamdal, 2003 .

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short- or Long-Course Radiotherapy?

S. Kaasa, R. Bremnes, U. Aasebø, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

S. Kaasa, S. Aamdal, R. Bremnes, 2005, Lung cancer.

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group

R. Bremnes, H H Strøm, R M Bremnes, 2013, British Journal of Cancer.

Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model

S. Kaasa, K. Bjordal, M. Hjermstad, 2004, Quality of Life Research.

Surgery for NSCLC stages T1-3N2M0 having preoperative pathologically verified N2 involvement: A prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group.

O. Hansen, T. Palshof, B. Bergman, 2013 .

Astroblastoma – a case report of a rare neuroepithelial tumor with complete remission after chemotherapy

S. Torp, S. Gulati, S. Sundstrøm, 2011, Clinical neuropathology.

Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.

S. Lydersen, S. Torp, C. Lindboe, 2005, Clinical neuropathology.